Evidence map›Paper›PMID 35429395›Full record

ArticleThe Journal of infectious diseases2022

Amplicon Sequencing as a Potential Surveillance Tool for Complexity of Infection and Drug Resistance Markers in Plasmodium falciparum Asymptomatic Infections.

Kevin Wamae, Kelvin M Kimenyi, Victor Osoti, Zaydah R de Laurent, Leonard Ndwiga, Oksana Kharabora, Nicholas J Hathaway, Jeffrey A Bailey, Jonathan J Juliano, Philip Bejon and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. UnderstandingiScience · 2026
    Article
  3. Article
  4. Article
  5. UnderstandingmedRxiv : the preprint server for health sciences · 2025
    Article
  6. Detection of novelMicrobial genomics · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Integrating targeted genetic markers to genotyping-by-sequencing for an ultimate genotyping tool.TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik · 2024
    Article
  11. A retrospective analysis ofAntimicrobial agents and chemotherapy · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Population structure and genetic connectivity ofFrontiers in epidemiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Kevin WamaeKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya.ORCID 0000-0001-7721-5534
Kelvin M KimenyiKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya.
Victor OsotiKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya.
Zaydah R de LaurentKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya.
Leonard NdwigaKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya.
Oksana KharaboraDivision of Infectious Diseases, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Nicholas J HathawayDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Jeffrey A BaileyDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA.
Jonathan J JulianoDivision of Infectious Diseases, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Philip BejonKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya.
Lynette Isabella Ochola-OyierKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya.
Kenya Medical Research Institute · KEUniversity of North Carolina at Chapel Hill · USBrown University · USUniversity of Massachusetts Chan Medical School · USUniversity of Nairobi · KE

Funding

Variation in Resistance and Fitness to Artemisinins in African MalariaR01AI121558 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, JONATHAN J · 2016 to 2020
$3.3M
Wellcome Trust 203077
6 · The paper itself

Abstract

backgroundGenotyping Plasmodium falciparum subpopulations in malaria infections is an important aspect of malaria molecular epidemiology to understand within-host diversity and the frequency of drug resistance markers.

methodsWe characterized P. falciparum genetic diversity in asymptomatic infections and subsequent first febrile infections using amplicon sequencing (AmpSeq) of ama1 in Coastal Kenya. We also examined temporal changes in haplotype frequencies of mdr1, a drug-resistant marker.

resultsWe found >60% of the infections were polyclonal (complexity of infection [COI] >1) and there was a reduction in COI over time. Asymptomatic infections had a significantly higher mean COI than febrile infections based on ama1 sequences (2.7 [95% confidence interval {CI}, 2.65-2.77] vs 2.22 [95% CI, 2.17-2.29], respectively). Moreover, an analysis of 30 paired asymptomatic and first febrile infections revealed that many first febrile infections (91%) were due to the presence of new ama1 haplotypes. The mdr1-YY haplotype, associated with chloroquine and amodiaquine resistance, decreased over time, while the NY (wild type) and the NF (modulates response to lumefantrine) haplotypes increased.

conclusionsThis study emphasizes the utility of AmpSeq in characterizing parasite diversity as it can determine relative proportions of clones and detect minority clones. The usefulness of AmpSeq in antimalarial drug resistance surveillance is also highlighted.

Indexed as

AntimalarialsMalariaMalaria, FalciparumAsymptomatic InfectionsDrug ResistanceHumansPlasmodium falciparumProtozoan ProteinsAntimalarialsProtozoan Proteinsama1antimalarial drug resistanceartemisinin-based combination therapyartemisinin resistancedeep sequencinggenetic diversitymdr1

Identifiers

PMID35429395
PMCPMC7613600
OpenAlexW4224100813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.